Detailed Quote
Questions on this company?
Become a Member
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: HI 5i Team,
In my USD account I hold REGN and ABBV @ 3.5%. I am considering adding ALXN growth. What is your opinion of this stock? If not this then any alternative? Dividends are not a priority.
Over the last 3 year of my membership, have immensely benefitted from your advice. Keep up the good work.
RR
In my USD account I hold REGN and ABBV @ 3.5%. I am considering adding ALXN growth. What is your opinion of this stock? If not this then any alternative? Dividends are not a priority.
Over the last 3 year of my membership, have immensely benefitted from your advice. Keep up the good work.
RR
Q: The stock down 11% but i can't find a reason. The rumour about Amgen was a week ago and Alxn's fundamentals look solid. Any ideas?
Q: My biotech holdings include Celegene at 3% and alexion at 1.5%. I am looking to obtain a basket of these stocks, the best in your opinion, as opposed to getting the sector etf.
My question are as follows:
1. Do you feel now is an opportune time to be adding to biotech, or has the sector run up too far?
2. If the time is right, what would be your top complementary picks to my current positions ( mid cap to large cap) and how many should I hold? Please advise what an adequate overall portfolio position would be for the sector, for an investor with a palate for moderate risk and a long way term view.
Thank you for your counsel,
Karim .
My question are as follows:
1. Do you feel now is an opportune time to be adding to biotech, or has the sector run up too far?
2. If the time is right, what would be your top complementary picks to my current positions ( mid cap to large cap) and how many should I hold? Please advise what an adequate overall portfolio position would be for the sector, for an investor with a palate for moderate risk and a long way term view.
Thank you for your counsel,
Karim .
Insiders
Share Information
SEC Filings
News and Media